VERVE THERAPEUTICS INC (VERV)
US92539P1012 - Common Stock
We assign a fundamental rating of 3 out of 10 to VERV. VERV was compared to 587 industry peers in the Biotechnology industry. VERV has a great financial health rating, but its profitability evaluates not so good. VERV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year VERV has reported negative net income.
VERV had a negative operating cash flow in the past year.
VERV had negative earnings in each of the past 5 years.
VERV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VERV has a better Return On Assets (-26.58%) than 75.77% of its industry peers.
The Return On Equity of VERV (-33.37%) is better than 79.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.58% | ||
| ROE | -33.37% | ||
| ROIC | N/A |
ROA(3y)-27.03%
ROA(5y)-45.74%
ROE(3y)-31.87%
ROE(5y)-99.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VERV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VERV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERV has been increased compared to 1 year ago.
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.09, we must say that VERV is in the distress zone and has some risk of bankruptcy.
VERV's Altman-Z score of 1.09 is fine compared to the rest of the industry. VERV outperforms 64.85% of its industry peers.
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.09 |
ROIC/WACCN/A
WACC9.14%
2.3 Liquidity
A Current Ratio of 17.24 indicates that VERV has no problem at all paying its short term obligations.
VERV has a Current ratio of 17.24. This is amongst the best in the industry. VERV outperforms 93.00% of its industry peers.
VERV has a Quick Ratio of 17.24. This indicates that VERV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 17.24, VERV belongs to the top of the industry, outperforming 93.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.24 | ||
| Quick Ratio | 17.24 |
3. Growth
3.1 Past
The earnings per share for VERV have decreased by -6.85% in the last year.
The Revenue has grown by 505.88% in the past year. This is a very strong growth!
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-2.99%
Revenue 1Y (TTM)505.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q409.31%
3.2 Future
Based on estimates for the next years, VERV will show a decrease in Earnings Per Share. The EPS will decrease by -0.49% on average per year.
Based on estimates for the next years, VERV will show a very strong growth in Revenue. The Revenue will grow by 47.34% on average per year.
EPS Next Y4.68%
EPS Next 2Y-1.66%
EPS Next 3Y-3.74%
EPS Next 5Y-0.49%
Revenue Next Year89.84%
Revenue Next 2Y13.08%
Revenue Next 3Y25.17%
Revenue Next 5Y47.34%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
VERV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VERV's earnings are expected to decrease with -3.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.66%
EPS Next 3Y-3.74%
5. Dividend
5.1 Amount
No dividends for VERV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VERVE THERAPEUTICS INC
NASDAQ:VERV (5/3/2024, 7:24:35 PM)
After market: 6.41 0 (0%)6.41
+0.26 (+4.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap537.93M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.58% | ||
| ROE | -33.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 17.24 | ||
| Quick Ratio | 17.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-6.85%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y4.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)505.88%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y